Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Cash from Operations: 2019-2025

Historic Cash from Operations for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to -$57.4 million.

  • Nurix Therapeutics' Cash from Operations fell 36.06% to -$57.4 million in Q3 2025 from the same period last year, while for Aug 2025 it was -$230.4 million, marking a year-over-year decrease of 137.16%. This contributed to the annual value of -$172.6 million for FY2024, which is 112.11% down from last year.
  • According to the latest figures from Q3 2025, Nurix Therapeutics' Cash from Operations is -$57.4 million, which was up 9.14% from -$63.2 million recorded in Q2 2025.
  • Over the past 5 years, Nurix Therapeutics' Cash from Operations peaked at $26.7 million during Q4 2023, and registered a low of -$63.2 million during Q2 2025.
  • In the last 3 years, Nurix Therapeutics' Cash from Operations had a median value of -$42.2 million in 2024 and averaged -$39.6 million.
  • As far as peak fluctuations go, Nurix Therapeutics' Cash from Operations slumped by 629.37% in 2022, and later surged by 170.32% in 2023.
  • Over the past 5 years, Nurix Therapeutics' Cash from Operations (Quarterly) stood at -$30.9 million in 2021, then declined by 22.79% to -$38.0 million in 2022, then skyrocketed by 170.32% to $26.7 million in 2023, then plummeted by 282.66% to -$48.8 million in 2024, then crashed by 36.06% to -$57.4 million in 2025.
  • Its Cash from Operations was -$57.4 million in Q3 2025, compared to -$63.2 million in Q2 2025 and -$61.1 million in Q1 2025.